Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00119626 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1700

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Stroke
Ischemic Attack, Transient

Interventions

DRUG: NXY-059

Sponsor

AstraZeneca